ETNI.US Entest Biomedical Inc
- Market cap
- USD 9.83K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Aug 2023.
Is ETNI.US undervalued?
Graham numberThe Graham number of Entest Biomedical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Entest Biomedical Inc fundamental analysis
No fundamental analysis for Entest Biomedical Inc yet.
Entest Biomedical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Entest Biomedical Inc
Entest Group, Inc. does not have significant operations. It intends to seek business opportunities to review and analyze for purposes of effecting a merger, acquisition, or other business combination with an operating company business. The company was formerly known as Entest Biomedical, Inc. and changed its name to Entest Group, Inc. in February 2018. Entest Group, Inc. was founded in 2008 and is based in Shenzhen, China.
Full company profileEntest Biomedical Inc financial statements
Entest Biomedical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - |
| Operating Income | -380K | -441K | -539K | -652K | -1.52M | -40.1K | - | - | - | - |
| EBITDA | -380K | -441K | 59.8K | 29.9K | 44.7K | 232K | - | - | - | - |
| Net Income | -1.42M | -485K | -507K | -559K | -1.48M | 192K | - | - | - | - |
| EPS | -0.14 | -0.03 | -0.01 | -0.01 | -0.03 | 0.00 | - | - | - | - |
| Balance Sheet | ||||||||||
| Total Assets | 10.7K | 20.2K | 23.9K | 336K | 9.31K | 0.00 | - | - | - | - |
| Total Liabilities | 690K | 808K | 1.00M | 319K | 255K | 32.7K | - | - | - | - |
| Shareholders' Equity | -679K | -787K | -979K | -39.5K | -246K | -32.7K | - | - | - | - |
| Cash & Short-term Investments | 734.00 | 2.16K | 859.00 | 86.6K | 267.00 | 0.00 | - | - | - | - |
| Total Debt | 383K | 414K | 456K | 13.5K | 19.6K | 21.2K | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.42M | -258K | -43.4K | -473K | -1.49M | -3.96K | - | - | - | - |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| Free Cash Flow | -1.42M | -258K | -43.4K | -473K | -1.49M | -3.96K | - | - | - | - |
| Ratios | ||||||||||
| ROA | -13,339.0% | -2,407.2% | -2,125.0% | -166.3% | -15,875.0% | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
Entest Biomedical Inc dividends
Entest Biomedical Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:150 on Jul 27, 2015.
Who owns Entest Biomedical Inc
Ownership data of Entest Biomedical Inc is not available yet.
Entest Biomedical Inc company profile
- Company name
- Entest Biomedical Inc
- Ticker
- ETNI.US
- Exchange
- USA Stocks
- Sector
- Financial Services
- Industry
- Capital Markets
- Fiscal year end
- August
- Address
- No. 911 Bao?an Book City, Shenzhen, China
- Phone
- 86 13709631109
- Website
- -
About Entest Biomedical Inc
Entest Group, Inc. does not have significant operations. It intends to seek business opportunities to review and analyze for purposes of effecting a merger, acquisition, or other business combination with an operating company business. The company was formerly known as Entest Biomedical, Inc. and changed its name to Entest Group, Inc. in February 2018. Entest Group, Inc. was founded in 2008 and is based in Shenzhen, China.
Entest Biomedical Inc management
3- Mr. Peiwen YuPresident, CEO & Director · born 1970
- Dr. Steven Josephs Ph.D.Chief Science Officer and Member of Advisory Board
- Dr. Feng LinDirector of Research and Member of Advisory Board